Achillion Reports First Quarter 2018 Financial Results and Management Transition
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500, Nasdaq futures rise on tech boost
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Oil rises on Iran war stalemate; near-term potential for further gains seen limited
- L3Harris CEO steps down amid conduct review, shares drop
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
- BOJ eyeing September rate hike, faster pace of tightening, sources say
Achillion Pharma (ACHN) Misses Q1 EPS by 1c; Joseph Truitt Appointed Chief Executive Officer
May 2, 2018 6:41 AM EDTAchillion Pharma (NASDAQ: ACHN) reported Q1 EPS of ($0.15), $0.01 worse than the analyst estimate of ($0.14).
Achillion today announced that Joseph Truitt, the Companys President and Chief Operating Officer, has been named Chief Executive Officer and will be appointed to the Companys Board of Directors. Milind S. Deshpande, Ph.D. will be stepping down from his role as Chief Executive Officer and resigning from the Board of Directors, and is expected to provide continued guidance and scientific support under a consulting agreement.
Dr. Deshpande has been at... More
